PTX Media related, page-1025

TAKE 2 (replica of above minus format issues)....

It's almost impossible to know how our collaboration with Thermo Fisher is going to play out on a corporate level. We (as SH) don't even know the details of the agreement. All we know is that TF has agreed to undertake R&D with PTX retainining the rights to any IP. The original (version 1) of the OmniCAR platform is patented by UPenn. Our optimised version (as it stands as per last year) is under review with patent pending. Whether the design work being undertaken in collaboration with TF adds further steps of optimisation (and improvement) enough to push the "novel" and "inventive" aspect/s of PTX's pending patent is yet to be determined.

Last year's ann states the following:-

"PTX signed an agreement with Thermo Fisher to accelerate development and commercialization of a highly scalable version of Prescient’s OmniCAR cell therapy platform. The agreement’s development plan will evaluate the potential of utilizing automated, closed cell therapy solutions to develop a novel process of manufacturing cell therapies on the OmniCAR platform using non-viral methods."

"A key Prescient objective is to create a 2nd generation of the OmniCAR platform by being able to manufacture OmniCAR cells with greater efficiency and lower costs that are suitable for tech transfer to GMP-licensed contract development and manufacturing organizations (CDMO)s globally. This is aligned with Prescient’s vision of decentralised manufacturing, which is best suited for multi-centre treatments, both during development and eventually for commercial roll-out."

I dare to say that the "new" IP that is to be derived from our collaborative R&D with TF will be used to solidify our patent application. I take it that's your thinking too,@DerrickJ? That the 2nd generation version of OmniCAR will ultimately be what will be patented. If that's the case, then I'm of the opinion that the move on PTX's part to publish our patent application and data was strategic.

The other aspect which is a total unknown in this collab work is CellPryme-M. Does the R&D work with TF incorporate our CP-M tech is that a process totally separate to the "closed" OmniCAR manufacturing process and undertaken immediately upon harvesting from the patient or human donor? Any thoughts here on this aspect?